InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Sims Andrew John Hugh MacIntyre, Chief Financial Officer. Officer active across 1 companies, notably Plus Therapeutics, INC.. Cumulatively, 8 filings have been logged. Total volume traded: €20k. The latest transaction was filed on 26 April 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations8 total
€1,8943,000 shares@ €0.63140.0053% mcap9.6% of flow
Common Stock
SEC:0001209191-22-025719:0·
Ideal exit: 21 Jan 2023 (T+270)
€1,9612,000 shares@ €0.98070.0054% mcap9.9% of flow
Common Stock
SEC:0001209191-22-015201:0·
Ideal exit: 26 Nov 2022 (T+270)
€1,6071,000 shares@ €1.607220.3% of flow
Common Stock
SEC:0001209191-21-062868·
Ideal exit: 30 Jul 2022 (T+270)
€1,6071,000 shares@ €1.60720.0045% mcap8.2% of flow
Common Stock
SEC:0001209191-21-062868:0·
Ideal exit: 30 Jul 2022 (T+270)
€2,8792,000 shares@ €1.439436.3% of flow
Common Stock
SEC:0001209191-21-061723·
Ideal exit: 23 Jul 2022 (T+270)
€2,8792,000 shares@ €1.43940.0080% mcap14.6% of flow
Common Stock
SEC:0001209191-21-061723:0·
Ideal exit: 23 Jul 2022 (T+270)
€3,4441,986 shares@ €1.733943.4% of flow
Common Stock
SEC:0001209191-21-048660·
Ideal exit: 23 Apr 2022 (T+270)
€3,4441,986 shares@ €1.73390.0096% mcap17.5% of flow
Common Stock
SEC:0001209191-21-048660:0·
Ideal exit: 23 Apr 2022 (T+270)
8 of 8 declarations
About Sims Andrew John Hugh MacIntyre
Sims Andrew John Hugh MacIntyre is Chief Financial Officer at PLUS THERAPEUTICS, INC. In this role, he is responsible for financial management and budgeting strategy for the company. His expertise in finance allows him to optimize financial performance and ensure regulatory compliance. Andrew plays a key role in strategic planning and financial results analysis.
